Tests tislelizumab with chemoradiotherapy for cervical cancer
Tests tislelizumab with radiation and chemotherapy in adults with advanced cervical cancer.
Plain-language title generated from the registry record
Registry title: Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer
Key facts
- Where
- Nanning, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 70 with stage IIIC2 cervical cancer that has not spread to other organs. It tests tislelizumab together with chemoradiotherapy as first treatment.
- Age
- 18 to 70 years
- Sex
- Women only
- Disease stage
- Squamous carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, 2018 FIGO stage IIIC2, with at least one measurable lesion and no metastatic disease. ECOG score 0-1.
- Earlier treatment
- Cannot have had earlier treatment with PD-1, PD-L1 or CTLA-4 antibodies, or other drugs targeting immunomodulatory receptors.
Main reasons for not taking part
- Another cancer in the past 5 years
- Active autoimmune disease or immune deficiency such as HIV infection
- Active infection needing treatment through the body
- Pregnant or breastfeeding
- Took part in a trial of another drug within 4 weeks
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT05511623, who can take part
Where in China
- First Affiliated Hospital of Guangxi Medical UniversityNanning, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- First Affiliated Hospital of Guangxi Medical University
- Trial code
- NCT05511623
- Record updated
- 11 September 2023
- Original description
To evaluate the efficacy and safety of tislelizumab combined with concurrent chemoradiotherapy in first-line treatment of stage IIIC2 cervical cancer.Read full original descriptionShow less
Efficacy and Safety of Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer
To evaluate the efficacy and safety of tislelizumab combined with concurrent chemoradiotherapy in first-line treatment of stage IIIC2 cervical cancer.
Inclusion: (1)18-70 years old; (2)Histologically confirmed squamous carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix; (3)Patients with 2018 FIGO stage IIIC2 cervical cancer; (4)At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST) 1.1; (5)Eastern Cooperative Oncology Group score 0-1; (6)No metastatic diseases; (7)Must have an average life expectancy of 6 months; (8)Participants must have normal organ and marrow function as defined below: (hemoglobin ≥90g/L,neutrophils ≥1.5×109/L, platelets ≥80×109/L, ALB≥30g/L, Total bilirubin≤1.5 x institutional upper limit of normal, AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal, Creatinine clearance≥60 mL/min; (9)Patients with menopause, or patients of reproductive potential were required to take effective contraceptive measures for the duration of the study and had a negative pregnancy test result, non-lactating women; (10)Patients volunteered to participate in the study and sign the informed consent.
Exclusion: Previously treatment with PD-1 and/or PD-L1, or CTLA-4 antibody, or other medications targeting immunomodulatory receptors; Patients with grade>2 unrelieved toxic reactions (based on National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0) caused by any previous treatment; Those who have participated in clinical trials with other drugs within 4 weeks; Patients with concomitant diseases or abnormal test results which interfere with the ability to receive anticancer therapy judged by the investigator; Diagnosed with any other cancer within the past 5 years; Known allergy to any component of the drug; Congenital or acquired immune deficiency (such as HIV infection); The presence of any active, known or suspected autoimmune disease (such as, but not limited to, interstitial pneumonia, uveitis, enteritis, hepatitis, arthritis, nephritis, hypophysitis, hyperthyroidism, hypothyroidism, etc.); Medical history of vitiligo; asthma which requires bronchodilators for medical intervention; Active infection requiring systemic treatment; With a history of myocardial infarction,stroke, unstable angina, decompensated heart failure, or deep vein thrombosis; Long-term uncured wounds or fractures; Major surgery or severe traumatic injury, fracture or ulcer within 4 weeks; With metastatic diseases; Liver/renal insufficiency; Those who have a history of psychotropic drug abuse and cannot get rid of it or those with mental disorders; Pregnant or lactating women; Patients could not gain the maximum benefit from this study judged by the investigator.